Skip to main content
. 2024 Aug 19;59(4):426–440. doi: 10.1159/000540919

Table 2.

Analysis of female prevalence comparison to male prevalence

Symptom Number of studies Female sample size Male sample size Female prevalence Male prevalence Risk Ratio (95% CI) p value
Fatigue 10 3,247 3,397 1,246 (38.37%) 912 (26.84%) 1.40 (1.22–1.6) <0.001
Headache 7 2,856 2,883 755 (26.43%) 551 (19.81%) 1.37 (1.12–1.67) 0.002
Anxeity 5 2,569 3,008 340 (13.23%) 318 (10.57%) 1.32 (0.91–1.92) 0.13
Depression 4 2,523 2,920 372 (14.74%) 261 (8.93%) 1.49 (1.2–1.86) <0.001
Brain-fog symptoms 7 2,863 3,173 486 (16.9%) 352 (11.09%) 1.38 (1.08–1.76) 0.011
Post-traumic stress disorder 1 137 240 42 (30.65%) 43 (17.90%) NE NE
Anosmia 5 2,563 2,993 313 (12.2%) 200 (6.66%) 1.61 (1.36–1.90) <0.001
Paresthesia 2 1,458 1,611 43 (2.9%) 40 (2.4%) NE NE
Dysgeusia 2 1,444 1,789 141 (9.76%) 102 (5.7%) NE NE
Vertigo 2 1,458 1,611 64 (4.3%) 60 (3.72%) NE NE
Visual Disturbances 2 1,458 1,611 49 (3.3%) 49 (3%) NE NE

CI, Confidence interval; NE, non estimable.

Bold entries in the table idicate a p value of ≤0.05.